177 related articles for article (PubMed ID: 21162536)
21. Synthesis and biological evaluation of neutral and zwitterionic 3-carboranyl thymidine analogues for boron neutron capture therapy.
Byun Y; Yan J; Al-Madhoun AS; Johnsamuel J; Yang W; Barth RF; Eriksson S; Tjarks W
J Med Chem; 2005 Feb; 48(4):1188-98. PubMed ID: 15715485
[TBL] [Abstract][Full Text] [Related]
22. Cytotoxicity and cell death pathways invoked by two new rhodium-ferrocene complexes in benign and malignant prostatic cell lines.
Weber B; Serafin A; Michie J; Van Rensburg C; Swarts JC; Bohm L
Anticancer Res; 2004; 24(2B):763-70. PubMed ID: 15161024
[TBL] [Abstract][Full Text] [Related]
23. "Four-potential" ferrocene labeling of PNA oligomers via click chemistry.
Hüsken N; Gasser G; Köster SD; Metzler-Nolte N
Bioconjug Chem; 2009 Aug; 20(8):1578-86. PubMed ID: 19586015
[TBL] [Abstract][Full Text] [Related]
24. The primary in vitro anticancer activity of "half-mustard type" phenothiazines in NCI's revised anticancer screening paradigm.
Wuonola MA; Palfreyman MG; Motohashi N; Kawase M; Gabay S; Gupta RR; Molnár J
Anticancer Res; 1998; 18(1A):337-48. PubMed ID: 9568100
[TBL] [Abstract][Full Text] [Related]
25. Boronated protohaemins: synthesis and in vivo antitumour efficacy.
Ol'shevskaya VA; Nikitina RG; Zaitsev AV; Luzgina VN; Kononova EG; Morozova TG; Drozhzhina VV; Ivanov OG; Kaplan MA; Kalinin VN; Shtil AA
Org Biomol Chem; 2006 Oct; 4(20):3815-21. PubMed ID: 17024289
[TBL] [Abstract][Full Text] [Related]
26. Ferrocene-mediated proton-coupled electron transfer in a series of ferrocifen-type breast-cancer drug candidates.
Hillard E; Vessières A; Thouin L; Jaouen G; Amatore C
Angew Chem Int Ed Engl; 2005 Dec; 45(2):285-90. PubMed ID: 16312004
[No Abstract] [Full Text] [Related]
27. Addition of ethynylferrocene to transition-metal complexes containing a chelating 1,2-dicarba-closo-dodecaborane-1,2-dichalcogenolate ligand--in vitro cooperativity of a ruthenium compound on cellular uptake of an anticancer drug.
Wu DH; Wu CH; Li YZ; Guo DD; Wang XM; Yan H
Dalton Trans; 2009 Jan; (2):285-90. PubMed ID: 19089009
[TBL] [Abstract][Full Text] [Related]
28. Relationship between electrochemical potentials and substitution reaction rates of ferrocene-containing β-diketonato rhodium(I) complexes; cytotoxicity of [Rh(FcCOCHCOPh)(cod)].
Conradie J; Swarts JC
Dalton Trans; 2011 Jun; 40(22):5844-51. PubMed ID: 21423964
[TBL] [Abstract][Full Text] [Related]
29. Synthesis, biochemical properties and molecular modelling studies of organometallic specific estrogen receptor modulators (SERMs), the ferrocifens and hydroxyferrocifens: evidence for an antiproliferative effect of hydroxyferrocifens on both hormone-dependent and hormone-independent breast cancer cell lines.
Top S; Vessières A; Leclercq G; Quivy J; Tang J; Vaissermann J; Huché M; Jaouen G
Chemistry; 2003 Nov; 9(21):5223-36. PubMed ID: 14613131
[TBL] [Abstract][Full Text] [Related]
30. Preparation and evaluation of carborane analogues of tamoxifen.
Beer ML; Lemon J; Valliant JF
J Med Chem; 2010 Nov; 53(22):8012-20. PubMed ID: 21028825
[TBL] [Abstract][Full Text] [Related]
31. Reactivity and antiproliferative activity of ferrocenyl-tamoxifen adducts with cyclodextrins against hormone-independent breast-cancer cell lines.
Buriez O; Heldt JM; Labbé E; Vessières A; Jaouen G; Amatore C
Chemistry; 2008; 14(27):8195-203. PubMed ID: 18668496
[TBL] [Abstract][Full Text] [Related]
32. Synthesis and cytotoxic activities of beta-carboline amino acid ester conjugates.
Zhao M; Bi L; Wang W; Wang C; Baudy-Floc'h M; Ju J; Peng S
Bioorg Med Chem; 2006 Oct; 14(20):6998-7010. PubMed ID: 16806943
[TBL] [Abstract][Full Text] [Related]
33. Remarkable anti-breast cancer activity of ferrocene tagged multi-functionalized 1,4-dihydropyrimidines.
Jadhav J; Juvekar A; Kurane R; Khanapure S; Salunkhe R; Rashinkar G
Eur J Med Chem; 2013 Jul; 65():232-9. PubMed ID: 23711834
[TBL] [Abstract][Full Text] [Related]
34. Design and synthesis of novel C14-hydroxyl substituted triptolide derivatives as potential selective antitumor agents.
Li Z; Zhou ZL; Miao ZH; Lin LP; Feng HJ; Tong LJ; Ding J; Li YC
J Med Chem; 2009 Aug; 52(16):5115-23. PubMed ID: 19637874
[TBL] [Abstract][Full Text] [Related]
35. Design of beta-carboline derivatives as DNA-targeting antitumor agents.
Guan H; Chen H; Peng W; Ma Y; Cao R; Liu X; Xu A
Eur J Med Chem; 2006 Oct; 41(10):1167-79. PubMed ID: 16790297
[TBL] [Abstract][Full Text] [Related]
36. Synthesis, characterization and in vitro antiproliferative activities of new 13-cis-retinoyl ferrocene derivatives.
Long B; Liang S; Xin D; Yang Y; Xiang J
Eur J Med Chem; 2009 Jun; 44(6):2572-6. PubMed ID: 19231037
[TBL] [Abstract][Full Text] [Related]
37. Ferrocenyl quinone methides as strong antiproliferative agents: formation by metabolic and chemical oxidation of ferrocenyl phenols.
Hamels D; Dansette PM; Hillard EA; Top S; Vessières A; Herson P; Jaouen G; Mansuy D
Angew Chem Int Ed Engl; 2009; 48(48):9124-6. PubMed ID: 19876986
[No Abstract] [Full Text] [Related]
38. Design, synthesis and discovery of 5-hydroxyaurone derivatives as growth inhibitors against HUVEC and some cancer cell lines.
Cheng H; Zhang L; Liu Y; Chen S; Cheng H; Lu X; Zheng Z; Zhou GC
Eur J Med Chem; 2010 Dec; 45(12):5950-7. PubMed ID: 20974505
[TBL] [Abstract][Full Text] [Related]
39. New ferrocene containing peptide conjugates: synthesis and effect on human leukemia (HL-60) cells.
Miklán Z; Szabó R; Zsoldos-Mády V; Reményi J; Bánóczi Z; Hudecz F
Biopolymers; 2007; 88(2):108-14. PubMed ID: 17266125
[TBL] [Abstract][Full Text] [Related]
40. WRC-213, an l-methionine-conjugated mitoxantrone derivative, displays anticancer activity with reduced cardiotoxicity and drug resistance: identification of topoisomerase II inhibition and apoptotic machinery in prostate cancers.
Hsiao CJ; Li TK; Chan YL; Hsin LW; Liao CH; Lee CH; Lyu PC; Guh JH
Biochem Pharmacol; 2008 Feb; 75(4):847-56. PubMed ID: 18035333
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
